Compare Cytokinetics Inc (CYTK) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Workiva Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Workiva Inc trades at $75.4 (market cap $4.01B). The key difference: Cytokinetics Inc is far larger — about 2.1× Workiva Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Workiva Inc for 21 Days on average.
| CYTK | WK | |
|---|---|---|
Market Cap | $8.62B | $4.01B |
Volume | 2,594,626 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $87.26 | $93.31 |
52-Week Low | $54.76 | $44.31 |
Typical Hold Time | 19 Days | 21 Days |
Enterprise Value | $8.72B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
WK trades at $71.53, up 1.95% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and analyst consensus of $86 price target. Revenue grew to $966M in 2026 with net income turning positive at $47M. Recent news highlights AI innovation and inclusion in major indices, supporting positive sentiment.
The outlook remains positive with 89% analyst buy ratings and improving profitability. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in the regulatory software space. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
